Mymetics Corp (MYMX)

[Work Harder]

eTheRNA has developed a proprietary lipid nanoparticle (LNP) platform to enable intravenous delivery of various (neo)antigens, which in combination with TriMix results in unprecedented immune responses.

Nice snag SP1, additionally below

https://www.prnewswire.com/news-releases/etherna-raises-eur-34-million-in-series-b-financing-to-accelerate-multiple-mrna-therapeutic-development-programs-through-to-clinical-proof-of-concept-301077454.html

Jacques-François Martin, Chief Executive of Mymetics said, "This patent complements very well the intellectual property portfolio around Mymetics' vaccine pipeline and broadens, in particular, our technology platform to develop other non-influenza virosome based vaccines. It is also an additional confirmation of the importance of our acquisition of Virosome Biologicals last year."

https://www.rttnews.com/1492116/mymetics-secures-new-patent-for-virosome-based-vaccines.aspx

Virosome engineering of colloidal particles and surfaces: bioinspired fusion to supported lipid layers

https://pubs.rsc.org/en/content/articlehtml/2016/nr/c5nr08169f

https://academic.oup.com/intimm/article/17/6/695/671220

https://europepmc.org/article/med/17355227

https://www.jimmunol.org/content/157/3/1028

Classifications

A61K9/127 Liposomes

https://patents.google.com/patent/EP1447080A1/en

https://patents.google.com/patent/WO2004071492A1/en

eTheRNA immunotherapies NV (‘eTheRNA’ or ‘The Company’), a clinical-stage company developing immunotherapies from its proprietary mRNA TriMix platform for the treatment of cancer and infectious diseases, today announced that it has successfully raised Euro 34 million in a Series B equity financing round. All existing investors – LSP (the Netherlands), PMV (Belgium), Boehringer Ingelheim Venture Fund (Germany), Fund+ (Belgium) and Omega Funds (USA) – are participating in the round. They are joined by Grand Decade, a BVI subsidiary owned by China Grand Pharmaceutical and Healthcare Holdings Ltd (‘GP(HK)’; HKSE Stock code 00512), BNP Paribas Fortis Private Equity (Belgium), Yijing Capital (China) and Novalis LifeSciences LLC (USA). GP(HK) and eTheRNA have also agreed outline terms for a possible exclusive strategic partnership for mRNA manufacturing, independent research and development, production and commercialization in Greater China.

https://www.etherna.be/news-archive2020/

to Grand Decade Developments Limited, a British Virgin Islands limited company and a wholly owned subsidiary of China Grand Pharmaceutical and Healthcare Holdings Limited

https://ir.oncosec.com/filings/all-sec-filings/content/0001493152-20-010178/ex3-1.htm?TB_iframe=true&height=auto&width=auto&preload=false

China Grand
Pharmaceutical company

Headquarters: Hong Kong
Founded: 1995
Subsidiaries: Wuhan Wuyao Pharmaceutical Co Ltd, MORE

Wuhan Grand Pharmaceutical Group Co.,Ltd .(Established in 1939), specializes in the manufacture and distribution of pharmaceutical ingredients, intermediates and preparations.

As the largest comprehensive pharmaceutical company in central China and a GMP certified manufacturer